Haifaa Abdulhaq, MD

Articles

Future Perspectives for the Treatment of Relapsed/Refractory DLBCL

February 24th 2025

A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year

Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape

February 17th 2025

A discussion of major challenges in using bispecific antibodies in the relapsed/refractory DLBCL setting, focusing on dosing, safety concerns like CRS, and step-up dosing strategies, along with insights on best practices for community clinics; followed by a review of sequencing bispecific antibodies and CAR T-cell therapies in third-line treatment, informed by recent studies on bispecific/CAR T sequencing

Academic Insights for the Treatment of Later Relapsed/Refractory DLBCL

February 17th 2025

An overview of third-line treatment options for DLBCL, including choices for patients who did not receive CAR T-cell therapy or transplant in second-line, strategies for those who progress after CAR T-cell or transplant, and the impact of bispecific antibodies and ADCs, with insights from key studies on Glofit and Epcor in relapsed/refractory DLBCL and their implications for patient selection and care.

Additional Perspectives Beyond CAR T-cell Regimens in Relapsed/Refractory DLBCL.: Bispecifics

February 10th 2025

A discussion of current trials on bispecific antibody therapies in DLBCL, highlighting key takeaways from STARGLO on Glofit+GemOx in relapsed/refractory disease, the potential role of bispecifics in second-line treatment, and the patient populations and care settings most likely to benefit from these emerging options.

Real World Perspectives: Considerations and Challenges for CAR T-cell Therapy in Relapsed/Refractory DLBCL

February 10th 2025

An overview of challenges with CAR T-cell therapy, including combating T-cell exhaustion, the pros and cons of outpatient administration, logistical barriers, and the role of polatuzumab in bridging therapy, along with a discussion of non-cellular second-line options such as pola+BR and findings from L-MIND compared to real-world data

Real World Perspectives: Outcomes for CAR T-cell Therapy in Relapsed/Refractory DLBCL

February 3rd 2025

A review of real-world outcomes for CAR T-cell therapies in the relapsed/refractory setting from ASH 2024, comparing them to clinical trial results and addressing safety management concerns, toxicities, and prophylactic treatment options in practice.

Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

February 3rd 2025

A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.

The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

January 27th 2025

An analysis of key updates on CAR T-cell therapy in DLBCL from ZUMA-7 and TRANSFORM trials, exploring its potential as a primary second-line option, along with insights into efficacy and safety data for transplant-ineligible patients from ALYCANTE and PILOT studies

Second-line Treatment Landscape in Relapsed/Refractory DLBCL

January 27th 2025

A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.

Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

January 20th 2025

A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.

Future Considerations for Front-line Treatment of DLBCL

January 20th 2025

An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.

The Evolving First-line Treatment Approach for DLBCL

January 15th 2025

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?

January 15th 2025

An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.

Emerging Updates in Front-line Treatment Approach of DLBCL

January 3rd 2025

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO)

December 24th 2024

Dr. Haifaa Abdulhaq presents results from the global Phase III STARGLO trial, demonstrating the superior overall survival, progression-free survival, and complete response rates of glofitamab combined with gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-based therapy (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma, with a tolerable safety profile.

Future Outlooks in the Treatment of R/R DLBCL

February 27th 2024

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Additional Data Updates from ASH 2023

February 20th 2024

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

Treatment Sequencing of Later Line Therapies in R/R DLBCL

February 20th 2024

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

R/R DLBCL: Safety Considerations for Bispecific Antibodies

February 13th 2024

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Bispecifics for Third Line Therapy of R/R DLBCL

February 13th 2024

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.